For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/WFZ865. CME/MOC credit will be available until February 27, 2025.
Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Brendon M. Stiles, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; Regeneron; and Pfizer.
Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.
Faculty/Planner
Balazs Halmos, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; and Pfizer.
Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
View all episodes
By PVI, PeerView Institute for Medical Education
5
33 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/WFZ865. CME/MOC credit will be available until February 27, 2025.
Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Brendon M. Stiles, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; Regeneron; and Pfizer.
Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.
Faculty/Planner
Balazs Halmos, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; and Pfizer.
Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
5 Listeners
3 Listeners
3 Listeners
11 Listeners
5 Listeners
28 Listeners
9 Listeners
3 Listeners
2 Listeners
4 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
2 Listeners
12 Listeners
2 Listeners